Genentech's Giredestrant Posts Positive Phase 3 Data Ahead Of November, December FDA Dates

Genentech, part of Roche Group, reported that detailed Phase 3 evERA trial results published in the New England Journal of Medicine showed giredestrant plus everolimus significantly improved progression-free survival in patients with ER-positive disease. The positive late-stage clinical outcome supports the regimen's potential in oncology, although the article excerpt does not provide numerical efficacy data or regulatory timelines.